Year in review 2010: Critical Care - infection

Critical Care

Volumn 15, Issue 6, 2011, Pages

  Pagani, Leonardo ^a,b   Afshari, Arash ^b,c   Harbarth, Stephan ^b  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTRIAXONE; ERTAPENEM; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CRITICALLY ILL PATIENT; EARLY DIAGNOSIS; HUMAN; INFECTION; INFLUENZA A (H1N1); INTENSIVE CARE; INTENSIVE CARE UNIT; MEDICAL LITERATURE; MYCOSIS; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; CRITICAL ILLNESS; METHODOLOGY;

CRITICAL CARE; CRITICAL ILLNESS; HUMANS; INFECTION;

EID: 82955205851     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10425     Document Type: Review

References (56)

1. Harbarth S, Haustein T. Year in review 2009: Critical Care--infection. Crit Care 2010, 14:240. 10.1186/cc9268, 3220050, 21122168.
2. Fischer JE, Harbarth S, Agthe AG, Benn A, Ringer SA, Goldmann DA, Fanconi S. Quantifying uncertainty: physicians' estimates of infection in critically ill neonates and children. Clin Infect Dis 2004, 38:1383-1390. 10.1086/420741, 15156475.
3. Leggieri N, Rida A, François P, Schrenzel J. Molecular diagnosis of bloodstream infections: planning to (physically) reach the bedside. Curr Opin Infect Dis 2010, 23:311-319.
4. Mancini N, Carletti S, Ghidoli N, Cichero P, Burioni R, Clementi M. The era of molecular and other non-culture-based methods in diagnosis of sepsis. Clin Microbiol Rev 2010, 23:235-251. 10.1128/CMR.00043-09, 2806664, 20065332.
5. Tissari P, Zumla A, Tarkka E, Mero S, Savolainen L, Vaara M, Aittakorpi A, Laakso S, Lindfors M, Piiparinen H, Maki M, Carder C, Huggett J, Gant V. Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study. Lancet 2010, 375:224-230. 10.1016/S0140-6736(09)61569-5, 20004964.
6. Dark PM, Dean P, Warhurst G. Bench-to-bedside review: the promise of rapid infection diagnosis during sepsis using polymerase chain reaction-based pathogen detection. Crit Care 2009, 13:217. 10.1186/cc7886, 2750130, 19664174.
7. Yanagihara K, Kitagawa Y, Tomonaga M, Tsukasaki K, Kohno S, Seki M, Sugimoto H, Shimazu T, Tasaki O, Matsushima A, Ikeda Y, Okamoto S, Aikawa N, Hori S, Obara H, Ishizaka A, Hasegawa N, Takeda J, Kamihira S, Sugahara K, Asari S, Murata M, Kobayashi Y, Ginba H, Sumiyama Y, Kitajima M. Evaluation of pathogen detection from clinical samples by real-time polymerase chain reaction using a sepsis pathogen DNA detection kit. Crit Care 2010, 14:R159. 10.1186/cc9234, 2945143, 20731880.
8. Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P. Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic use and bacterial resistance, 2001 to 2008. Crit Care 2010, 14:R113. 10.1186/cc9062, 2911759, 20546564.
9. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Morgenthaler NG, Schoenenberg R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B, . for the ProHOSP Study Group Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010, 14:R106. 10.1186/cc9055, 2911752, 20529344, for the ProHOSP Study Group.
10. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 2011, 66(S2):ii33-40.
11. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010, 14:203. 10.1186/cc8155, 2875480, 20236471.
12. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008, 177:498-505.
13. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M, . PRORATA Trial Group Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474. 10.1016/S0140-6736(09)61879-1, 20097417, PRORATA Trial Group.
14. van Nieuwkoop C, Bonten TN, van't Wout JW, Kuijper EJ, Groenveld GH, Becker MJ, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Leyten EMS, van Dissel JT. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care 2010, 14:R206. 10.1186/cc9328, 3220019, 21083886.
15. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44:1009-1034. 10.2165/00003088-200544100-00002, 16176116.
16. Giannoni E, Moreillon P, Cotting J, Moessinger A, Bille J, Décosterd L, Zanetti G, Majcherczyk P, Bugnon D. Prospective determination of plasma imipenem concentrations in critically ill children. Antimicrob Agents Chemother 2006, 50:2563-2568. 10.1128/AAC.01149-05, 1489785, 16801447.
17. Pea F, Viale P. Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?. Crit Care 2009, 13:214. 10.1186/cc7774, 2717408, 19519961.
18. Choi EY, Hun JW, Lim C-M, Koh Y, Kim S-H, Choi S-H, Kim YS, Kim M-N, Hong S-B. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med 2011, 37:639-647. 10.1007/s00134-011-2130-7, 21253703.
19. Taccone FS, Laterre P-F, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent J-L, Jacobs F. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010, 14:R53. 10.1186/cc8945, 2887170, 20370907.
20. Layeux B, Taccone FS, Fagnoul D, Vincent JL, Jacobs F. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010, 54:4939-4941. 10.1128/AAC.00441-10, 2976156, 20823287.
21. Gálvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, Illanes V, Llanos O, Castro J. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011, 38:146-151. 10.1016/j.ijantimicag.2011.03.022, 21612894.
22. Taccone FS, de Backer D, Laterre P-F, Spapen H, Dugernier T, Delattre I, Wallemacq P, Vincent J-L, Jacobs F. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011, 37:531-535. 10.1016/j.ijantimicag.2011.01.026, 21489756.
23. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance. Implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010, 49:1-16. 10.2165/11318140-000000000-00000, 20000886.
24. Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent J-L, Jacobs F. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011, 15:R137. 10.1186/cc10257, 3219006, 21649882.
25. Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, Roberts JA, Lipman J. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011, 15:R139. 10.1186/cc10262, 3219011, 21651804.
26. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 2011, 37:632-638. 10.1007/s00134-010-2105-0, 21136037.
27. Taccone FS, Laterre P-F, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent J-L, Jacobs F. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14:R126. 10.1186/cc9091, 2945087, 20594297.
28. Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol 2010, 6:1017-1031. 10.1517/17425255.2010.506187, 20636224.
29. Lodise TP, Drusano GL. Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit. Crit Care Clin 2011, 27:1-18. 10.1016/j.ccc.2010.11.003, 21144983.
30. Lodise TP, Butterfield J. Use of pharmacodynamic principles to inform β-lactam dosing: 'S' does not always mean success. J Hosp Med 2011, 6(Suppl 1):S16-S23.
31. Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2011, 55:1606-1610. 10.1128/AAC.01330-10, 3067164, 21300830.
32. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011, 50:99-110. 10.2165/11539220-000000000-00000, 21142293.
33. Chapuis TM, Giannoni E, Majcherczyk PA, Chioléro R, Schaller M-D, Berger MM, Bolay S, Décosterd LA, Bugnon D, Moreillon P. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14:R51. 10.1186/cc8941, 2887166, 20359352.
34. Adembri C, Novelli A. Pharmacokinetic and pharmacodynamic parameters of antimicrobials. Potential for providing dosing regimens that are less vulnerable to resistance. Clin Pharmacokinet 2009, 48:517-528. 10.2165/10895960-000000000-00000, 19705922.
35. Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens IC, Harbarth S, Jarlier V, Levy SB, N'doye B, Pittet D, Richtmann R, Seto WH, van der Meer JW, Voss A. Society's failure to protect a precious resource: antibiotics. Lancet 2011, 378:369-371. 10.1016/S0140-6736(11)60401-7, 21477855.
36. Morel J, Casoetto J, Jospé R, Aubert G, Terrana R, Dumont A, Molliex S, Auboyer C. De-escalation as part of global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care 2010, 14:R225. 10.1186/cc9373, 3219998, 21167047.
37. Leone M, Garcin F, Bouvenot J, Boyadjev I, Visintini P, Albanèse J, Martin C. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 2007, 35:379-385. 10.1097/01.CCM.0000253404.69418.AA, 17205011.
38. Dellit TH, Chan JD, Skerret SJ, Nathens AB. Development of a guideline for the management of ventilator-associated pneumonia based on local microbiological findings and impact of the guidelines on antimicrobial use practices. Infect Control Hosp Epidemiol 2008, 29:525-533. 10.1086/588160, 18510462.
39. Pagani L, Falciani M, Aschbacher R. Use of microbiologic findings to manage antimicrobials in the intensive care unit. Infect Control Hosp Epidemiol 2009, 30:309-311. 10.1086/595731, 19215201.
40. Raineri E, Pan A, Mondello P, Acquarolo A, Candiani A, Crema L. Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. Am J Infect Control 2008, 36:283-290. 10.1016/j.ajic.2007.06.009, 18455049.
41. Augustin P, Kermarrec N, Muller-Serieys C, Lasocki S, Chosidow D, Marmuse J-P, Valin N, Desmonts J-M, Montravers P. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care 2010, 14:R20. 10.1186/cc8877, 2875535, 20156360.
42. Owens RC. Antimicrobial stewardship: application in the intensive care unit. Infect Dis Clin North Am 2009, 23:683-702. 10.1016/j.idc.2009.04.015, 19665090.
43. Lawrence KL, Kollef MH. Antimicrobial stewardship in the intensive care unit. Advances and obstacles. Am J Respir Crit Care Med 2009, 179:434-438. 10.1164/rccm.200809-1394CP, 19136370.
44. Prospero E, Barbadoro P, Esposto E, Manso E, Martini E, Savini S, Scaccia F, Tantucci L, Pelaia P, D'Errico MM. Extended-spectrum beta-lactamases Klebsiella pneumoniae: multimodal infection control program in intensive care units. J Prev Med Hyg 2010, 51:110-115.
45. Jain R, Kralovic SM, Evans ME, Ambrose M, Simbartl LA, Obrosky DS, Render ML, Fryberg RW, Jernigan JA, Muder RR, Miller LJ, Roselle GA. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med 2011, 364:1419-1430. 10.1056/NEJMoa1007474, 21488764.
46. Huskins WC, Huckabee CM, O'Grady NP, Murray P, Kopetskie H, Zimmer L, Walker ME, Sincowitz-Cochran RL, Jernigan JA, Samore M, Wallace D, Goldmann DA, . for the STAR*ICU Trial Investigators Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011, 364:1407-1418. 10.1056/NEJMoa1000373, 21488763, for the STAR*ICU Trial Investigators.
47. Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect Dis Clin North Am 2011, 25:245-260. 10.1016/j.idc.2010.11.011, 21316003.
48. George P, Morris AM. Pro/con debate: should antimicrobial stewardship programs be adopted universally in the intensive care unit?. Crit Care 2010, 14:205. 10.1186/cc8219, 2875495, 20236505.
49. Morace G, Borghi E. Fungal infections in ICU patients: epidemiology and the role of diagnostics. Minerva Anestesiol 2010, 76:950-956.
50. Bassetti M, Mikulska M, Viscoli C. Bench-to-bedside review: Therapeutic management of invasive candidiasis in the intensive care unit. Crit Care 2010, 14:244. 10.1186/cc9239, 3220045, 21144007.
51. Leroy O, Mira J-P, Montravers P, Gangneux J-P, Lortholary O, . for the AmarCand Study Group Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care 2010, 14:R98. 10.1186/cc9033, 2911735, 20507569, for the AmarCand Study Group.
52. Trof RJ, Beishuizen A, Debets-Ossenkopp YP, Girbes AR, Groeneveld AB. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med 2007, 33:1694-1703. 10.1007/s00134-007-0791-z, 2039828, 17646966.
53. He H, Ding L, Li F, Zhan Q. Clinical features of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study. Crit Care 2011, 15:R5. 10.1186/cc9402, 3222032, 21211008.
54. Van Kerkhove MD, Vandemaele KAH, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, Carlino LO, Owen R, Paterson B, Pelletier L, Vachon J, Gonzales C, Hongjie Y, Zijian F, Chuang SK, Au A, Buda S, Krause G, Haas W, Bonmarin I, Taniguichi K, Nakajima K, Shobayashi T, Takayama Y, Sunagawa T, Heraud JM, Orelle A, Palacios E, van der Sande MAB, Lieke Wielders CCH, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011, 8:e1001053. 10.1371/journal.pmed.1001053, 3130021, 21750667.
55. Kuster SP, Katz KC, Blair J, Downey J, Drews SJ, Finkelstein S, Fowler R, Green K, Gubbay J, Hassan K, Lapinsky SE, Mazzulli T, McRitchie D, Pataki J, Plevneshi A, Powis J, Rose D, Sarabia A, Simone C, Simor A, McGeer A. When should a diagnosis of influenza be considered in adults requiring intensive care unit admission? Results from population-based active surveillance in Toronto. Crit Care 2011, 15:R182. 10.1186/cc10331, 21798012.
56. Han K, Ma H, An X, Su Y, Chen J, Lian Z, Zhao J, Zhu BP, Fontaine RE, Feng Z, Zeng G. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis 2011, 53:326-333. 10.1093/cid/cir398, 21810744.